SHIP-deficient mice are severely osteoporotic due to increased numbers of hyper-resorptive osteoclasts

[1]  M. Huber,et al.  SHIP Negatively Regulates IgE + Antigen-Induced IL-6 Production in Mast Cells by Inhibiting NF-κB Activity1 , 2002, The Journal of Immunology.

[2]  Y. Xu,et al.  The Phox homology (PX) domain, a new player in phosphoinositide signalling. , 2001, The Biochemical journal.

[3]  L. Hocking,et al.  Genomewide search in familial Paget disease of bone shows evidence of genetic heterogeneity with candidate loci on chromosomes 2q36, 10p13, and 5q35. , 2001, American journal of human genetics.

[4]  J. Whisstock,et al.  Characterization of an adapter subunit to a phosphatidylinositol (3)P 3-phosphatase: Identification of a myotubularin-related protein lacking catalytic activity , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[5]  L. Cantley,et al.  Translocating Tubby , 2001, Science.

[6]  J. Hurley,et al.  Subcellular targeting by membrane lipids. , 2001, Current opinion in cell biology.

[7]  R. Parsons,et al.  PTEN: life as a tumor suppressor. , 2001, Experimental cell research.

[8]  S. Schurmans,et al.  The lipid phosphatase SHIP2 controls insulin sensitivity , 2001, Nature.

[9]  S. Takeshita,et al.  TNF-alpha induces osteoclastogenesis by direct stimulation of macrophages exposed to permissive levels of RANK ligand. , 2000, The Journal of clinical investigation.

[10]  S. Teitelbaum,et al.  Bone resorption by osteoclasts. , 2000, Science.

[11]  N. Athanasou,et al.  Osteoclast differentiation from circulating mononuclear precursors in Paget's disease is hypersensitive to 1,25-dihydroxyvitamin D(3) and RANKL. , 2000, Bone.

[12]  G. Krystal,et al.  Lipid phosphatases in the immune system. , 2000, Seminars in immunology.

[13]  S. Takeshita,et al.  Identification and Characterization of the New Osteoclast Progenitor with Macrophage Phenotypes Being Able to Differentiate into Mature Osteoclasts , 2000, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[14]  D. Lucas,et al.  Structure, function, and biology of SHIP proteins. , 2000, Genes & development.

[15]  P. Geusens,et al.  Perspectives on bone mechanical properties and adaptive response to mechanical challenge. , 1999, Journal of clinical densitometry : the official journal of the International Society for Clinical Densitometry.

[16]  Matthew J. Silva,et al.  Growing C57Bl/6 Mice Increase Whole Bone Mechanical Properties by Increasing Geometric and Material Properties , 1999, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[17]  T. Sasaki,et al.  SHIP is a negative regulator of growth factor receptor-mediated PKB/Akt activation and myeloid cell survival. , 1999, Genes & development.

[18]  S. Morony,et al.  OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis , 1999, Nature.

[19]  S. Majumdar,et al.  Trabecular Bone Mineral and Calculated Structure of Human Bone Specimens Scanned by Peripheral Quantitative Computed Tomography: Relation to Biomechanical Properties , 1998, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[20]  M. Huber,et al.  The src homology 2-containing inositol phosphatase (SHIP) is the gatekeeper of mast cell degranulation. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[21]  G. Krystal,et al.  Targeted disruption of SHIP leads to hemopoietic perturbations, lung pathology, and a shortened life span. , 1998, Genes & development.

[22]  D. Lacey,et al.  Osteoprotegerin Ligand Is a Cytokine that Regulates Osteoclast Differentiation and Activation , 1998, Cell.

[23]  K Yano,et al.  Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[24]  R. Dubose,et al.  A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function , 1997, Nature.

[25]  Brian R. Wong,et al.  TRANCE Is a Novel Ligand of the Tumor Necrosis Factor Receptor Family That Activates c-Jun N-terminal Kinase in T Cells* , 1997, The Journal of Biological Chemistry.

[26]  I. Babic,et al.  The Src Homology 2 (SH2) Domain of SH2-containing Inositol Phosphatase (SHIP) Is Essential for Tyrosine Phosphorylation of SHIP, Its Association with Shc, and Its Induction of Apoptosis* , 1997, The Journal of Biological Chemistry.

[27]  S. Mckercher,et al.  Osteopetrosis in mice lacking haematopoietic transcription factor PU.1 , 1997, Nature.

[28]  G. Krystal,et al.  Cloning and characterization of human SHIP, the 145-kD inositol 5-phosphatase that associates with SHC after cytokine stimulation. , 1996, Blood.

[29]  G. Roodman.  Paget's disease and osteoclast biology. , 1996, Bone.

[30]  P. Majerus,et al.  The 145-kDa protein induced to associate with Shc by multiple cytokines is an inositol tetraphosphate and phosphatidylinositol 3,4,5-triphosphate 5-phosphatase. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[31]  A. DeFranco,et al.  Activation-induced Association of a 145-kDa Tyrosine-phosphorylated Protein with Shc and Syk in B Lymphocytes and Macrophages (*) , 1996, The Journal of Biological Chemistry.

[32]  Sakae Tanaka,et al.  Wortmannin, a specific inhibitor of phosphatidylinositol‐3 kinase, blocks osteoclastic bone resorption , 1995, FEBS letters.

[33]  L. Williams,et al.  An alternative to SH2 domains for binding tyrosine-phosphorylated proteins. , 1994, Science.

[34]  G. Krystal,et al.  Multiple cytokines stimulate the binding of a common 145-kilodalton protein to Shc at the Grb2 recognition site of Shc , 1994, Molecular and cellular biology.

[35]  R. Aebersold,et al.  B cell antigen receptor cross-linking induces phosphorylation of the p21ras oncoprotein activators SHC and mSOS1 as well as assembly of complexes containing SHC, GRB-2, mSOS1, and a 145-kDa tyrosine-phosphorylated protein. , 1994, Journal of immunology.

[36]  R. Salgia,et al.  Shc phosphorylation in myeloid cells is regulated by granulocyte macrophage colony-stimulating factor, interleukin-3, and steel factor and is constitutively increased by p210BCR/ABL. , 1994, The Journal of biological chemistry.

[37]  M. Drezner,et al.  Bone histomorphometry: Standardization of nomenclature, symbols, and units: Report of the asbmr histomorphometry nomenclature committee , 1987 .

[38]  K. Kumar.  Paget's disease of bone. , 1986, Calcified tissue international.

[39]  L. McManus,et al.  Identification and characterization of osteoclast-like cells and their progenitors in cultures of feline marrow mononuclear cells , 1984, The Journal of cell biology.

[40]  A. Vignery,et al.  Dynamic histomorphometry of alveolar bone remodeling in the adult rat , 1980, The Anatomical record.

[41]  D H COLLINS,et al.  PAGET'S DISEASE OF BONE: INCIDENCE AND SUBCLINICAL FORMS , 1956 .

[42]  M. Horowitz,et al.  Local Regulators of Bone: IL-1, TNF, Lymphotoxin, Interferon-γ, IL-8, IL-10, IL-4, the LIF/IL-6 Family, and Additional Cytokines , 2002 .

[43]  R. Wallace,et al.  Mutations in TNFRSF11A, affecting the signal peptide of RANK, cause familial expansile osteolysis , 2000, Nature Genetics.

[44]  A. M. Parfitt,et al.  Bone Histomorphometry: System for Standardization of Nomenclature, Symbols, and Units , 1988 .

[45]  S. Niida,et al.  BriefDefinitive Report Essential Role of Macrophage Colony-Stimulating Factor in the Osteoclast Differentiation Supported by , 2022 .